tetano
Editor, Senior Moderator
MMWR Morb Mortal Wkly Rep
. 2020 Aug 21;69(33):1139-1143.
doi: 10.15585/mmwr.mm6933a3.
Mass Testing for SARS-CoV-2 in 16 Prisons and Jails - Six Jurisdictions, United States, April-May 2020
Liesl M Hagan, Samantha P Williams, Anne C Spaulding, Robin L Toblin, Jessica Figlenski, Jeanne Ocampo, Tara Ross, Heidi Bauer, Justine Hutchinson, Kimberley D Lucas, Matthew Zahn, Chun Chiang, Timothy Collins, Alexis Burakoff, Juli Bettridge, Ginger Stringer, Randolph Maul, Kristen Waters, Courtney Dewart, Jennifer Clayton, Sietske de Fijter, Radha Sadacharan, Linda Garcia, Naomi Lockett, Kirstin Short, Laxman Sunder, Senad Handanagic
Abstract
Preventing coronavirus disease 2019 (COVID-19) in correctional and detention facilities* can be challenging because of population-dense housing, varied access to hygiene facilities and supplies, and limited space for isolation and quarantine (1). Incarcerated and detained populations have a high prevalence of chronic diseases, increasing their risk for severe COVID-19-associated illness and making early detection critical (2,3). Correctional and detention facilities are not closed systems; SARS-CoV-2, the virus that causes COVID-19, can be transmitted to and from the surrounding community through staff member and visitor movements as well as entry, transfer, and release of incarcerated and detained persons (1). To better understand SARS-CoV-2 prevalence in these settings, CDC requested data from 15 jurisdictions describing results of mass testing events among incarcerated and detained persons and cases identified through earlier symptom-based testing. Six jurisdictions reported SARS-CoV-2 prevalence of 0%-86.8% (median = 29.3%) from mass testing events in 16 adult facilities. Before mass testing, 15 of the 16 facilities had identified at least one COVID-19 case among incarcerated or detained persons using symptom-based testing, and mass testing increased the total number of known cases from 642 to 8,239. Case surveillance from symptom-based testing has likely underestimated SARS-CoV-2 prevalence in correctional and detention facilities. Broad-based testing can provide a more accurate assessment of prevalence and generate data to help control transmission (4).
. 2020 Aug 21;69(33):1139-1143.
doi: 10.15585/mmwr.mm6933a3.
Mass Testing for SARS-CoV-2 in 16 Prisons and Jails - Six Jurisdictions, United States, April-May 2020
Liesl M Hagan, Samantha P Williams, Anne C Spaulding, Robin L Toblin, Jessica Figlenski, Jeanne Ocampo, Tara Ross, Heidi Bauer, Justine Hutchinson, Kimberley D Lucas, Matthew Zahn, Chun Chiang, Timothy Collins, Alexis Burakoff, Juli Bettridge, Ginger Stringer, Randolph Maul, Kristen Waters, Courtney Dewart, Jennifer Clayton, Sietske de Fijter, Radha Sadacharan, Linda Garcia, Naomi Lockett, Kirstin Short, Laxman Sunder, Senad Handanagic
- PMID: 32817597
- DOI: 10.15585/mmwr.mm6933a3
Abstract
Preventing coronavirus disease 2019 (COVID-19) in correctional and detention facilities* can be challenging because of population-dense housing, varied access to hygiene facilities and supplies, and limited space for isolation and quarantine (1). Incarcerated and detained populations have a high prevalence of chronic diseases, increasing their risk for severe COVID-19-associated illness and making early detection critical (2,3). Correctional and detention facilities are not closed systems; SARS-CoV-2, the virus that causes COVID-19, can be transmitted to and from the surrounding community through staff member and visitor movements as well as entry, transfer, and release of incarcerated and detained persons (1). To better understand SARS-CoV-2 prevalence in these settings, CDC requested data from 15 jurisdictions describing results of mass testing events among incarcerated and detained persons and cases identified through earlier symptom-based testing. Six jurisdictions reported SARS-CoV-2 prevalence of 0%-86.8% (median = 29.3%) from mass testing events in 16 adult facilities. Before mass testing, 15 of the 16 facilities had identified at least one COVID-19 case among incarcerated or detained persons using symptom-based testing, and mass testing increased the total number of known cases from 642 to 8,239. Case surveillance from symptom-based testing has likely underestimated SARS-CoV-2 prevalence in correctional and detention facilities. Broad-based testing can provide a more accurate assessment of prevalence and generate data to help control transmission (4).